AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

OTCMKTS:REPRRepro-Med Systems Stock Price, Forecast & News

$10.86
+0.15 (+1.40 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.28
Now: $10.86
$10.88
50-Day Range
$5.28
MA: $8.76
$12.38
52-Week Range
$1.35
Now: $10.86
$4.26
Volume225,096 shs
Average Volume36,047 shs
Market Capitalization$433.18 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.4
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:REPR
CUSIPN/A
Phone845-469-2042

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.35 million
Cash Flow$0.09 per share
Book Value$0.23 per share

Profitability

Net Income$910,000.00

Miscellaneous

Employees75
Market Cap$433.18 million
Next Earnings DateN/A
OptionableNot Optionable

Receive REPR News and Ratings via Email

Sign-up to receive the latest news and ratings for REPR and its competitors with MarketBeat's FREE daily newsletter.

Repro-Med Systems (OTCMKTS:REPR) Frequently Asked Questions

How has Repro-Med Systems' stock been impacted by COVID-19 (Coronavirus)?

Repro-Med Systems' stock was trading at $8.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, REPR stock has increased by 26.0% and is now trading at $10.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Repro-Med Systems?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repro-Med Systems in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Repro-Med Systems.

How were Repro-Med Systems' earnings last quarter?

Repro-Med Systems, Inc. (OTCMKTS:REPR) issued its quarterly earnings data on Tuesday, August, 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.02. The firm had revenue of $5.35 million for the quarter. Repro-Med Systems had a return on equity of 7.63% and a net margin of 0.17%. View Repro-Med Systems' earnings history.

Has Repro-Med Systems been receiving favorable news coverage?

Headlines about REPR stock have been trending very negative on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Repro-Med Systems earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutRepro-Med Systems.

Who are some of Repro-Med Systems' key competitors?

What other stocks do shareholders of Repro-Med Systems own?

Who are Repro-Med Systems' key executives?

Repro-Med Systems' management team includes the following people:
  • Mr. Daniel S. Goldberger, Exec. Chairman (Age 60)
  • Mr. Donald B. Pettigrew, CEO, Pres & Chief Commercial Officer (Age 51)
  • Ms. Karen Fisher, CFO, Treasurer & Corp. Sec. (Age 53)
  • Mr. Manuel A. Marques, Chief Operating Officer (Age 46)
  • Mr. Steven Kamphausen, Global VP of Sales & Marketing

What is Repro-Med Systems' stock symbol?

Repro-Med Systems trades on the OTCMKTS under the ticker symbol "REPR."

Who are Repro-Med Systems' major shareholders?

Repro-Med Systems' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.37%) and Raymond James & Associates (0.03%). Company insiders that own Repro-Med Systems stock include Arthur J Radin, James M Beck and Joseph M Jr Manko. View institutional ownership trends for Repro-Med Systems.

Which major investors are buying Repro-Med Systems stock?

REPR stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, and Raymond James & Associates. Company insiders that have bought Repro-Med Systems stock in the last two years include Arthur J Radin, James M Beck, and Joseph M Jr Manko. View insider buying and selling activity for Repro-Med Systems.

How do I buy shares of Repro-Med Systems?

Shares of REPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Repro-Med Systems' stock price today?

One share of REPR stock can currently be purchased for approximately $10.86.

How big of a company is Repro-Med Systems?

Repro-Med Systems has a market capitalization of $433.18 million and generates $17.35 million in revenue each year. Repro-Med Systems employs 75 workers across the globe.

What is Repro-Med Systems' official website?

The official website for Repro-Med Systems is www.rmsmedicalproducts.com.

How can I contact Repro-Med Systems?

Repro-Med Systems' mailing address is 24 CARPENTER RD, CHESTER NY, 10918. The company can be reached via phone at 845-469-2042 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.